

**Date: 30 December 2025**

To,

Corporate relationship Department,

BSE Limited,

1<sup>st</sup> Floor, Rotunda Building

P.J Towers Dalal Street, Fort,

Mumbai 400001

National Stock Exchange of India, Limited

Exchange Plaza, 5<sup>th</sup> Floor,

Plot No. C/1, G Block, Bandra-Kurla Complex,

Bandra (E),

Mumbai 400051

**Stock Code: BSE – 530549 / NSE – SHILPAMED**

Dear Sir/Ma'am,

**Sub: Ex-parte ad-interim injunction order regarding pharmaceutical drug product containing Ruxolitinib and/or Ruxolitinib Salts API****Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the Exchanges that the Company- Shilpa Medicare Ltd., Shilpa Pharma Lifesciences Ltd- a material subsidiary and FTF Pharma Pvt Ltd- a wholly owned subsidiary- has received an *ex parte* ad-interim injunction Order from the Hon'ble High Court of Delhi, New Delhi restraining the Company from manufacturing, stockpiling, exporting, offering for sale and/or supplying, directly or indirectly, the pharmaceutical drug product containing the compound Ruxolitinib and/or Ruxolitinib Salts API along with any other form or compound or formulation which would amount to infringement of the Suit Patent bearing No. IN269841

Further, Local Commissioner and its team visited the office premises of the Company to inspect and took relevant copies of ledgers, stock registers etc.

The Company fully co-operated with the officials during the proceedings and responded to the clarifications and details sought by them.

We wish to clarify that the said product was utilized for research purposes only, and there is no financial impact on the Company from this development. The business operations of the Company continued as usual and were not impacted due to the search.

The details as required under Clause 20 of Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as Annexure A.

The above information is also available on the website of the Company [www.vbshilpa.com](http://www.vbshilpa.com).

**For SHILPA MEDICARE LIMITED****Ritu Tiwary****Company Secretary & Compliance Officer**

**Form A**

**Disclosure regarding receipt of communication from regulatory, statutory, enforcement or judicial authority under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sr. No.	Particulars	Details
1.	Name of the authority	High Court of Delhi, New Delhi
2.	Nature and details of the action(s) taken, initiated or order(s) passed	Restraining the Company, Shilpa Pharma Lifesciences Ltd, a material subsidiary and FTF Pharma Pvt Ltd, a wholly owned subsidiary from using, manufacture, stockpiling, importing, selling, offering for sale/supply, exporting, beyond that is permissible under Section 107A of the Patent Act, 1970, of "Ruxolitinib alone or in any form or any product including a compound comprising "Ruxolitinib" in India which would amount to infringement of the Suit Patent bearing No. IN269841.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	29 December 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Alleged violation of Patent Infringement IN269841 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines and Pyrrolo [2,3B] Pyrimidines as Janus Kinase Inhibitors
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No Financial impact
6.	Action(s) taken by listed company with respect to the communication	The Company has duly acknowledged receipt of the ex parte ad interim injunction order and has taken necessary steps to comply with the directions contained therein.
7.	Any other relevant information	The Company is evaluating its legal options, including filing appropriate responses or appeals, as advised by counsel.